Clinical Trial Update: Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update evaluating the safety and preliminary efficacy of metabolically armed CD19 CAR-T cells (Meta10-19) in relapsed/refractory CD19-p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Meta10-19 metabolically armed CD19 CAR-T cells

Snippet

Sponsor: The Children's Hospital of Zhejiang University School of Medicine | Conditions: Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma | EARLY_Phase 1 | Status: RECRUITING